权益分类	功能权益	普通用户	{{item.name}}会员
{{category.name}}	{{benefitItem.name}}

Defining molecular and gene-regulatory dysregulation in Down Syndrome tissues and models

定义唐氏综合症组织和模型中的分子和基因调节失调

基本信息

批准号：
10433667
负责人：
Luis de la Torre-Ubieta
金额：
$ 19.44万
依托单位：
UNIVERSITY OF CALIFORNIA LOS ANGELES
依托单位国家：
美国
项目类别：
财政年份：
2022
资助国家：
美国
起止时间：
2022-03-10 至 2024-02-28
项目状态：
已结题

来源：
https://reporter.nih.gov/project-details/10433667
关键词：
Affect Age Architecture Atlases Automobile Driving Autopsy Biological Brain Cell Line Cell Nucleus Cells Chromatin Chromatin Structure Chromosome 21 Cluster Analysis Cognitive deficits Collection Data Data Set Development Disease Disease Progression Disease model Distal Down Syndrome Embryo Enhancers Epigenetic Process Etiology Experimental Models Foundations Future Gene Dosage Gene Expression Gene Expression Profile Gene Expression Regulation Gene Mutation Genes Genomics Goals Human Impairment In Vitro Individual Joints Knowledge LGALS3BP gene Language Language Development Lead Learning Maps Memory Methylation Methyltransferase Modeling Molecular Molecular Profiling Morphogenesis Morphology Neocortex Neurodevelopmental Disorder Neuroglia Neurons Newborn Infant Pathogenesis Pathology Pathway interactions Patients Pregnancy Process Proteins Publishing Regulator Genes Regulatory Element Reporting Research Resolution Role Sampling Small Nuclear RNA Technology Testing Therapeutic Time TimeLine Tissue Model Tissue-Specific Gene Expression Tissues arm base brain cell brain tissue cell fate specification cell type epigenome epigenomics experimental study gene regulatory network human model in vitro Model in vivo mRNA Differential Displays multiple omics nerve stem cell neurodevelopment neurogenesis neuropathology novel progenitor sex stem cell biology stem cell model stem cells synaptogenesis therapy development transcription factor transcriptome transcriptome sequencing treatment strategy

项目摘要

PROJECT ABSTRACT Down syndrome (DS) is a neurodevelopmental disorder causing cognitive deficits including impaired learning and memory, and language development, affecting 1 in 750 newborns. DS is caused by triplication of chromosome 21 (T21), leading to altered gene dosage, and to changes in the proportion of brain cell types, and in neuronal morphology and maturation, suggesting a neurodevelopmental etiology. However, the underlying molecular mechanisms causing the observed neuropathology and functional deficits are still largely unknown. Progress has been hindered by the overall complexity of brain architecture, an incomplete knowledge of the cell types and molecular pathways dysregulated in DS during development, and limited human-relevant experimental models. Moreover, bulk transcriptome and epigenome profiling indicates that T21 not only alters gene dosage within the locus, but also leads to broad changes in gene expression and may lead to altered gene regulatory dynamics. Based on these data, we hypothesize that increased chr21 gene dosage alters global gene expression in neural progenitors, changing neural cell fate specification and differentiation. Here, we leverage novel genomic technologies including joint single-nucleus transcriptome (snRNAseq), single-nucleus chromatin accessibility (snATACseq) profiling, and single-cell joint chromatin interaction and methylation profiling (sc-m3C-seq), as well as primary human neural progenitors (phNPCs), a validated model of human corticogenesis, to test this hypothesis. We will first define cell-specific molecular and gene-regulatory dysregulation in DS by performing joint snRNAseq, snATACseq and sc-m3C-seq in a collection of control and DS developing neocortex, at a time period of peak neurogenesis. This comprehensive multi-omic profiling will uncover changes in cell composition and cell-specific gene expression signatures in DS neocortex as well as reveal perturbations in cellular lineage maps and specification. By integrating single-cell expression and epigenetic profiles we will define the proximal and distal gene regulatory elements, as well as the transcription factors driving DS disease mechanisms. Finally, we will leverage a unique collection of DS patient-derived and control phNPC lines to model disease in vitro in order to characterize neural progenitor proliferation and specification in DS, as well as changes in neuronal morphogenesis and synaptogenesis. We perform joint snRNAseq and snATACseq over a differentiation timeline that recapitulates embryonic to mid-gestation corticogenesis in order to interrogate cellular, molecular and gene regulatory dysregulation in DS and directly compare this model with in vivo DS mechanisms. Altogether, we present a comprehensive project providing an in-depth cell biological and molecular characterization of DS progression using in vivo tissues and a human-relevant model, and establishes this model for future mechanistic interrogation. The long-term goal of this research is to provide the foundational molecular knowledge that will ultimately contribute to the development of treatments for DS.

项目摘要